The aldosterone-renin screening market is forecasted to grow from USD 574.8 million in 2025 to USD 1,109.7 million by 2035, at a CAGR of 6.8% during the forecast period. The aldosterone-renin ...

With its demonstrated clinical benefits and superior selectivity profile, SC0062 is positioned to potentially become a ...

On May 7, 2025, the American College of Rheumatology (ACR) released the full guideline for diagnosing, monitoring, and treating lupus nephritis (LN), which appeared in Arthritis & Rheumatology.

A phase 2 trial evaluated the efficacy and safety of lorundrostat in hypertensive patients with chronic kidney disease (CKD) and albuminuria.